{"product_id":"cell-therapy-market-by-type-autologous-and-allogeneic-by-therapy-mesenchymal-stem-cell-therapy-fibroblast-cell-therapy-hematopoietic-stem-cell-therapy-and-other-therapies-by-application-musculoskeletal-malignancies-cardiovascular-dermatology","title":"Cell Therapy Market, By Type (Autologous and Allogeneic), By Therapy (Mesenchymal Stem Cell Therapy, Fibroblast Cell Therapy, Hematopoietic Stem Cell Therapy, and Other Therapies), By Application (Musculoskeletal, Malignancies, Cardiovascular, Dermatology","description":"\u003cp\u003eCell Therapy Market, By Type (Autologous and Allogeneic), By Therapy (Mesenchymal Stem Cell Therapy, Fibroblast Cell Therapy, Hematopoietic Stem Cell Therapy, and Other Therapies), By Application (Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, and Other Applications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028\u003c\/p\u003e\n\n\u003cp\u003eCellular therapy is the transplantation of human cells to replace or repair damaged tissue and\/or cells. With new technologies and innovative products, many different types of cells can be used as part of a therapy\/treatment for a variety of diseases and conditions. Moreover, cell-based therapies hold great potential for replacing, repairing, restoring, and\/or regenerating damaged tissues, cells, and\/or organs. Thus, there is an increase in demand for cell-based therapies.\u003c\/p\u003e\n\n\u003cp\u003eMarket Dynamics:\u003c\/p\u003e\n\n\u003cp\u003eIncrease in incidence\/prevalence of chronic diseases, growing adoption of regenerative medicine, rise in focus on the development of cell therapies, increasing number of clinical trials, and outbreak of COVID-19 across the globe is expected to drive growth of the global cell therapy market.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, in May 2022, The European Commission (EC) approved Janssen’s CAR-T therapy, Carvykti, for adults with heavily pre-treated, relapsed and refractory multiple myeloma, marking the treatment’s first approval outside of the U.S. Moreover, in May 2022, The U.S. Food and Drug Administration (FDA) approved Novartis’s Kymriah (CAR) T-cell therapy) for the treatment of cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.\u003c\/p\u003e\n\n\u003cp\u003eKey features of the study: This report provides in-depth analysis of the global cell therapy market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market. This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players. It profiles key players in the global cell therapy market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies. Key companies covered as a part of this study include Stempeutics Research Pvt. Ltd., Medipost Co. Ltd., Nipro Corporation, Dendreon Pharmaceuticals LLC, Organogenesis Inc., Novartis AG, Vericel Corporation, Allogene Therapeutics Inc., Gilead Sciences Inc. (Kite Pharma Inc.), and Takeda Pharmaceutical Company Limited (TiGenix). Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics. The global cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts. Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell therapy market.Detailed Segmentation: Global Cell Therapy Market, By Type:AutologousAllogeneic Global Cell Therapy Market, By Therapy:Mesenchymal Stem Cell TherapyFibroblast Cell TherapyHematopoietic Stem Cell TherapyOther Therapies Global Cell Therapy Market, By Application:MusculoskeletalMalignanciesCardiovascularDermatology and WoundsOther Applications Global Cell Therapy Market, By Geography:North AmericaEuropeAsia-PacificMiddle East and AfricaSouth America Company Profiles:Stempeutics Research Pvt. Ltd.Medipost Co. Ltd.Nipro CorporationDendreon Pharmaceuticals LLCOrganogenesis Inc.Novartis AGVericel CorporationAllogene Therapeutics Inc.Gilead Sciences Inc. (Kite Pharma Inc.)Takeda Pharmaceutical Company Limited (TiGenix)\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"December, 2022 \/ 168 Pages \/ MCW16225333","offer_id":47639647027506,"sku":null,"price":5400.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/cell-therapy-market-by-type-autologous-and-allogeneic-by-therapy-mesenchymal-stem-cell-therapy-fibroblast-cell-therapy-hematopoietic-stem-cell-therapy-and-other-therapies-by-application-musculoskeletal-malignancies-cardiovascular-dermatology","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}